Business Greeting Cards Humorus Article

Boeing Buys Insitu To Expand Capabilities In Unmanned Aircraft

Boeing says Insitu's technologies and advanced capabilities in rapid prototyping and manufacturing are driving its revenue to an anticipated $150 million this year, 70 percent higher than in 2007, and have it well positioned for the future.

"Increasingly our customers are seeking advanced unmanned aerial solutions to address a wide range of requirements for ISR missions," said Jim Albaugh, president and CEO of Boeing Integrated Defense Systems. "The Boeing-Insitu team has been successfully delivering much-needed capability to the warfighter in a changing threat environment. Bringing these outstanding teams together will accelerate deployment of the next generation of unmanned systems to our US and allied service members."

Terms of the cash transaction were not disclosed. more

Global Clinical Trials Business Report & Analysis 2008-2018

Contract research organisations (CROs) are playing increasingly vital roles on behalf of manufacturers in the global drug development process, from conducting Phase I trials to post-marketing studies. It is often difficult for pharmaceutical and biotech companies to decide which CRO to offer a contract to. The market is due to undergo rapid change over the coming years, with different companies approaching the challenges in different ways. The CRO market, however, continues to grow steadily at an average 10% yearly growth rate. Visiongain predicts that there remains a sufficient growth opportunity for both mainstream and other CROs.
Why You Should Buy This Report:
In Global Clinical Trial Business 2008-2018 you will receive the following essential information for understanding the clinical trial business:


The value of the clinical trial business market and its principal market segments from 2008 to 2018
Which current or future therapies that will drive the market for clinical trial business from 2008 to 2018
Market drivers and restraints, including a comprehensive SWOT analysis
Comprehensive views of key opinion leaders on clinical trial business
The companies involved in clinical trial business and their business strategy
Forecasts for revenue in each of the phases of clinical trial business
The present state of clinical trial business and future trends there
What contract research opportunities exist for market entrants, both established companies and newcomers
The main concerns for outsourcing clinical trials to CROs
Ways to improve cost-effectiveness of clinical trial business
Changes in clinical trial regulations
Focus on drug safety issues. more

Canadian dollar turns lower as greenback rallies

"The industrial product prices data don't really play a big role in the Bank of Canada's policy, it tends to tell us more about corporate profitability than inflation pressure," said Doug Porter, deputy chief economist at BMO Capital Markets.

"Having said that, it's still definitely on the high side and notable that the Canadian dollar didn't really get any support from that."

As in recent weeks, it was ongoing pressure on oil prices and a stronger U.S. dollar that weighed on the Canadian dollar on Wednesday.

Traders were keeping an eye on oil prices, which slipped to $122 a barrel ahead of U.S. data that is expected to show rising fuel inventories and weak demand. Continued...

Business Greeting Cards Humorus